checkAd

     398  0 Kommentare Adaptimmune Receives Access to Priority Medicines (PRIME) Regulatory Support for its SPEAR® T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma - Seite 3

    Adaptimmune Contacts 

    Will Roberts 
    Vice President, Investor Relations 
    T:  (215) 825-9306  
    E: will.roberts@adaptimmune.com

    Lesen Sie auch

    Margaret Henry 
    Head of PR 
    T: +44 (0)1235 430036 
    Mobile: +44 (0)7710 304249 
    E: margaret.henry@adaptimmune.com



    This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
    The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
    Source: Adaptimmune Therapeutics plc via Globenewswire
    HUG#2031658
    Seite 3 von 3


    Diskutieren Sie über die enthaltenen Werte


    GlobeNewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Verfasst von GlobeNewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Adaptimmune Receives Access to Priority Medicines (PRIME) Regulatory Support for its SPEAR® T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma - Seite 3 New Initiative Provides Access to Scientific Advice and Supports Accelerated Assessment for Therapies Targeting Unmet Medical Needs PHILADELPHIA, Pa. and OXFORD, UK, July 28, 2016 (GLOBE NEWSWIRE) - Adaptimmune Therapeutics plc (Nasdaq:ADAP), a …